Acrturus Therapeutics Holdings Inc. Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET
Company Participants
Joseph Payne - President and Chief Executive Officer
Andrew Sassine - Chief Financial Officer
Pad Chivukula - Chief Scientifc Officer and Chief Operating Officer
Conference Call Participants
Pete Stavropoulos - Cantor Fitzgerald
Nick Abbott - Wells Fargo
Kumaraguru Raja - Brookline Capital Markets
Yale Jen - Laidlaw and Company
Yigal Nochomovitz - Citigroup
Steven Seedhouse - Raymond James
Operator
Good day and welcome to the Arcturus Therapeutics Second Quarter 2022 Financial Update and Pipeline Progress Call. Today's conference is being recorded.
At this time, I would like to turn the conference over to [indiscernible]. Please go ahead, sir.
Unidentified Company Representative
Thank you, Sara. Good afternoon and welcome to Arcturus Therapeutics Second Quarter 2022 Financial Update and Pipeline Progress Call. Thank you all for joining us. Today's call will be led by Joseph Payne, our President and CEO, and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO, will join in for the Q&A session.
Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance and achievements to differ materially from those expressed or implied by the statements.
Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our Forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, August 9, 2022. Arcturus specifically disclaims any obligation to update such statements to reflect future information, events or circumstances.
With that, I'll now turn the call over to Joe.
Joseph Payne
Thank you and good afternoon to all. Thank you for joining Arcturus' Q2 quarterly call. My comments today will begin with a brief summary of the business case for our vaccine platform, followed by highlighting our recent progress on our pipeline, including additional details per program before I turn the time over to Andy for financial updates.
Business case for our vaccine platform continues to mature and gain momentum. We begin by re-emphasizing our low dose level. A lower dose level of only five micrograms potentially means improved safety benefits and higher manufacturing related profit margins. Our vaccine platform is also devoid of an adjuvant and therefore captures all of the potential safety benefits and manufacturing simplicity associated with that.